Akorn Recalls Cromolyn Sodium Ophthalmic Solution Over Stability Studies
Akorn Inc. is recalling all lots of Cromolyn Sodium Ophthalmic Solution, USP 4% due to manufacturing deviations. The firm went out of business and could no longer continue required stability studies.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The recall is precautionary and compliance-based, driven by the firm's inability to complete stability studies after business closure rather than a demonstrated safety defect or adverse event.
Plain-English summary
Akorn Inc. is recalling all lots of Cromolyn Sodium Ophthalmic Solution, USP 4% in 10 mL bottles due to Current Good Manufacturing Practice (CGMP) deviations. The firm went out of business and could no longer continue the stability studies required to demonstrate the product's safety and efficacy throughout its shelf life.
The recall affects all lots distributed nationwide in the United States and Puerto Rico. Patients currently using this medication should contact their healthcare provider to discuss alternative treatments and determine whether they should continue using their current supply.
The recalled product
- Product
- Cromolyn Sodium Ophthalmic Solution, USP, 4%, 10 mL bottles, Rx Only, Manufactured by: Akorn Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · stability unverified
See all →- HighFluticasone Propionate Nasal Spray Recalled Due to Manufacturing Quality Concerns
FDA (Drugs) · 2023-06-07
- ModerateFerrous Sulfate Iron Supplement Drops Recalled for Manufacturing Stability Issues
FDA (Drugs) · 2023-06-07
- HighTrihexyphenidyl Hydrochloride Oral Solution Recalled for Unverified Stability
FDA (Drugs) · 2023-06-07
- HighNeomycin and Polymyxin B Eye Ointment Recalled for Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighClobetasol Propionate Ointment recalled due to manufacturing compliance failures
FDA (Drugs) · 2023-06-07